INNOVENT ANNOUNCES PHASE 3 RESTORE-3 STUDY OF SYCUME® (TEPROTUMUMAB N01 INJECTION) MET PRIMARY ENDPOINT IN INACTIVE THYROID EYE DISEASE

Reuters · 2d ago

Please log in to view news